Genotype 4 and the global challenge of hepatitis C treatment

doi:10.1016/S2468-1253(16)30006-1

Comment

. 2016 Sep;1(1):3-4.

doi: 10.1016/S2468-1253(16)30006-1. Epub 2016 Jun 16.

Genotype 4 and the global challenge of hepatitis C treatment

Stephen Ryder¹, Sarah Pett², Graham S Cooke³

Affiliations

¹ NIHR Biomedical Research Unit in Gastrointestinal and Liver Diseases at Nottingham University Hospitals NHS Trust and The University of Nottingham, Nottingham, UK.
² Institute of Clinical Trials and Methodology, University College London, London, UK; Kirby Institute, University of New South Wales, NSW, Australia.
³ Imperial College London, London W2 1NY, UK. Electronic address: g.cooke@imperial.ac.uk.

PMID: 28404109
DOI: 10.1016/S2468-1253(16)30006-1

Free article

Comment

Genotype 4 and the global challenge of hepatitis C treatment

Stephen Ryder et al. Lancet Gastroenterol Hepatol. 2016 Sep.

Free article

. 2016 Sep;1(1):3-4.

doi: 10.1016/S2468-1253(16)30006-1. Epub 2016 Jun 16.

Authors

Stephen Ryder¹, Sarah Pett², Graham S Cooke³

Affiliations

¹ NIHR Biomedical Research Unit in Gastrointestinal and Liver Diseases at Nottingham University Hospitals NHS Trust and The University of Nottingham, Nottingham, UK.
² Institute of Clinical Trials and Methodology, University College London, London, UK; Kirby Institute, University of New South Wales, NSW, Australia.
³ Imperial College London, London W2 1NY, UK. Electronic address: g.cooke@imperial.ac.uk.

PMID: 28404109
DOI: 10.1016/S2468-1253(16)30006-1

No abstract available

PubMed Disclaimer

Comment on

Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
Asselah T, Hézode C, Qaqish RB, ElKhashab M, Hassanein T, Papatheodoridis G, Feld JJ, Moreno C, Zeuzem S, Ferenci P, Yu Y, Redman R, Pilot-Matias T, Mobashery N. Asselah T, et al. Lancet Gastroenterol Hepatol. 2016 Sep;1(1):25-35. doi: 10.1016/S2468-1253(16)30001-2. Epub 2016 Jun 16. Lancet Gastroenterol Hepatol. 2016. PMID: 28404108 Clinical Trial.
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Waked I, Shiha G, Qaqish RB, Esmat G, Yosry A, Hassany M, Soliman R, Mohey MA, Allam N, Zayed N, Asselah T, Hall C, Redman R, Mobashery N, Doss W. Waked I, et al. Lancet Gastroenterol Hepatol. 2016 Sep;1(1):36-44. doi: 10.1016/S2468-1253(16)30002-4. Epub 2016 Jun 16. Lancet Gastroenterol Hepatol. 2016. PMID: 28404110 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Spiral, Imperial College Digital Repository
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Genotype 4 and the global challenge of hepatitis C treatment

Affiliations

Genotype 4 and the global challenge of hepatitis C treatment

Authors

Affiliations

Comment on

Similar articles

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical